(Reuters) - Biosite's board told Beckman that it considered a $92.50-per-share bid by Inverness, which makes home pregnancy tests and fertility monitoring kits, superior to Beckman Coulter's $90-per-share offer, Beckman said.
Biosite shares, which had risen on hopes of a higher bid, fell 3 percent in premarket trading to $91.60 from Monday's Nasdaq close of $94.66.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment